TG THERAPEUTICS, INC. Increase (Decrease) in Accounts Payable and Accrued Liabilities
TG THERAPEUTICS, INC. (TGTX) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of $99.36 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-08-05
- TG THERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-06-30 was $65.35M, a 692.85% increase year-over-year.
- TG THERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-03-31 was $34.02M, a 47.81% decline year-over-year.
- TG THERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-12-31 was $2.01M.
- TG THERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was -$19.55M, a 267.53% decline year-over-year.
- TG THERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2025 was $55.88M, a 144.67% increase from fiscal 2024.
- TG THERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was $22.84M, a 11794.79% increase from fiscal 2023.
- TG THERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was $192.00K.
- TG THERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2022 was -$11.01M, a 168.85% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $65.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $99.36M 10-Q · filed 2026-08-05 | $101.37M derived: sum of 3 quarters · filed 2026-08-05 | $81.82M derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2026-03-31 | $34.02M 10-Q · filed 2026-05-06 | $36.02M derived: sum of 2 quarters · filed 2026-05-06 | $16.48M derived: sum of 3 quarters · filed 2026-05-06 | $24.72M derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2025-12-31 | $2.01M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | -$17.54M derived: sum of 2 quarters · filed 2026-02-27 | -$9.30M derived: sum of 3 quarters · filed 2026-08-05 | $55.88M 10-K · filed 2026-02-27 | ||
| 2025-09-30 | -$19.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$11.31M derived: sum of 2 quarters · filed 2026-08-05 | $53.87M 10-Q · filed 2025-11-05 | $15.86M derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2025-06-30 | $8.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $73.42M 10-Q · filed 2026-08-05 | $71.15M 10-Q · filed 2025-08-08 | $35.41M derived: sum of 3 quarters · filed 2026-08-05 | $47.08M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-03-31 | $65.18M 10-Q · filed 2026-05-06 | $65.58M 10-Q · filed 2025-05-09 | $27.16M derived: sum of 2 quarters · filed 2026-05-06 | $38.83M derived: sum of 3 quarters · filed 2026-05-06 | $47.79M derived: sum of 4 quarters · filed 2026-05-06 | |
| 2024-12-31 | -$38.01M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | -$26.34M derived: sum of 2 quarters · filed 2026-02-27 | -$17.38M derived: sum of 3 quarters · filed 2026-02-27 | $22.84M 10-K · filed 2026-02-27 | ||
| 2024-09-30 | $11.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $20.63M derived: sum of 2 quarters · filed 2025-11-05 | $60.85M 10-Q · filed 2025-11-05 | $63.41M derived: sum of 4 quarters · filed 2026-02-27 | ||
| 2024-06-30 | $8.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | $49.18M 10-Q · filed 2025-08-08 | $51.74M derived: sum of 3 quarters · filed 2026-02-27 | $30.24M derived: sum of 4 quarters · filed 2026-02-27 | ||
| 2024-03-31 | $40.22M 10-Q · filed 2025-05-09 | $42.79M derived: sum of 2 quarters · filed 2026-02-27 | $21.28M derived: sum of 3 quarters · filed 2026-02-27 | $30.56M derived: sum of 4 quarters · filed 2026-02-27 | ||
| 2023-12-31 | $2.56M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | -$18.94M derived: sum of 2 quarters · filed 2026-02-27 | -$9.67M derived: sum of 3 quarters · filed 2026-02-27 | $192.00K 10-K · filed 2026-02-27 | ||
| 2023-09-30 | -$21.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$12.23M derived: sum of 2 quarters · filed 2024-11-07 | -$2.37M 10-Q · filed 2024-11-07 | |||
| 2023-06-30 | $9.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $19.14M 10-Q · filed 2024-08-09 | ||||
| 2023-03-31 | $9.86M 10-Q · filed 2024-05-06 | |||||
| 2022-12-31 | -$11.01M 10-K · filed 2025-03-03 | |||||
| 2021-12-31 | $15.99M 10-K · filed 2024-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |